Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.
East Africa
Neglected Tropical Diseases Program
medicine safety
pharmacovigilance
public health program
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
17 02 2021
17 02 2021
Historique:
received:
22
01
2021
revised:
10
02
2021
accepted:
12
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
24
4
2021
Statut:
epublish
Résumé
Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.
Identifiants
pubmed: 33671293
pii: ijerph18041941
doi: 10.3390/ijerph18041941
pmc: PMC7922898
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Global Health. 2018 Nov 16;14(1):109
pubmed: 30445979
Wkly Epidemiol Rec. 2015 Sep 18;90(38):489-504
pubmed: 26387149
J Clin Med. 2020 May 21;9(5):
pubmed: 32455556
Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130434
pubmed: 24821920
Drug Saf. 2013 Feb;36(2):75-81
pubmed: 23329541
Drug Saf. 2020 Apr;43(4):339-350
pubmed: 31919794
Public Health. 2012 Mar;126(3):233-236
pubmed: 22325616
Trop Med Health. 2014 Jun;42(2 Suppl):21-4
pubmed: 25425947
Lancet Glob Health. 2018 Oct;6(10):e1054-e1055
pubmed: 30223977
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319
pubmed: 25412180
BMC Public Health. 2017 May 22;17(1):484
pubmed: 28532397
PLoS Negl Trop Dis. 2018 Nov 21;12(11):e0006929
pubmed: 30462639
PLoS Negl Trop Dis. 2009 Aug 25;3(8):e412
pubmed: 19707588
Pathogens. 2020 Nov 06;9(11):
pubmed: 33172114
Infect Dis Poverty. 2017 Nov 20;6(1):158
pubmed: 29151362
Clin Ther. 2014 Mar 1;36(3):421-4
pubmed: 24612943
Pathogens. 2020 Dec 21;9(12):
pubmed: 33371488